Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first treatment ...

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...

ROOT, Switzerland, October 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial ...

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.

NovoCure's TTFields showed mixed clinical results in NSCLC, with minor overall survival improvement, questioning its broader adoption beyond glioblastoma. Financially, NovoCure remains strong with ...

On Tuesday, H.C. Wainwright upgraded shares of NovoCure Ltd. (NASDAQ: NASDAQ:NVCR) from Neutral to Buy, setting a price target of $30.00. The upgrade followed the recent FDA approval of NovoCure's ...

In trading on Tuesday, shares of NovoCure Ltd (Symbol: NVCR) crossed above their 200 day moving average of $16.73, changing hands as high as $19.33 per share. NovoCure Ltd shares are currently ...

Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains the same with $40.00. Larry Biegelsen has given ...

From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical field medical device to include the treatment of metastatic non-small cell lung cancer.

Novocure shares are surging 35% after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. Interactive Brokers ...

FDA approves NovoCure's Optune Lua for metastatic non-small cell lung cancer after platinum-based regimen. Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months.